Neue Studien aus / über Deutschland

Neue Psoriasis-Studien, die bei Pubmed veröffentlicht wurden – mit dem zusätzlichen Stichwort „german“

• Dokumentation der Psoriasis in der Routineversorgung – Expertenkonsens zu einem deutschen Datensatz
  No abstract
• Screening auf Depression bei Psoriasis-Patienten während einer dermatologischen Konsultation: ein erster Schritt in Richtung Behandlung
  No abstract
• Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19
  CONCLUSIONS AND RELEVANCE: In this cohort study, TNF inhibitor monotherapy was associated with a lower risk of adverse COVID-19 outcomes compared with other commonly prescribed immunomodulatory treatment regimens among individuals with IMIDs.
• Psoriasis erhöht Risiko für Atemwegsinfektionen
  No abstract
• Documentation of psoriasis in routine care – expert consensus on a German data set
  CONCLUSIONS: The consensus recommendation of a standard, an optimal and an optional data set for routine care of psoriasis intends to be a decision-making aid and an orientation for both daily practice and further development of documentation systems.
• Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document
  CONCLUSIONS: A clear treatment decision making framework is vital to improve management of psoriasis.KEY MESSAGESPsoriasis characteristics, patients and physicians opinions/needs and treatment adherence influence treatment goals.Different disease indexes could be used to assess treatment response but absolute PASI is preferredIn general psoriasis treatment failure should be considered if PASI75 response is not reached.
• Increased Skin Clearance and Quality of Life Improvement with Brodalumab Compared with Ustekinumab in Psoriasis Patients with Aggravating Lifestyle Factors
  CONCLUSIONS: Higher levels of complete skin clearance and QoL were achieved and maintained with brodalumab versus ustekinumab in patients with moderate-to-severe psoriasis, regardless of the presence of lifestyle risk factors.
• Targeting cytokines and immune checkpoints in atherosclerosis with monoclonal antibodies
  Over the past fifteen years, treatments using monoclonal antibodies specifically targeting cytokines have been developed to treat chronic inflammatory diseases, including rheumatoid arthritis or psoriasis, both associated with increased cardiovascular risk. The cardiovascular impact of these therapies allows us to validate the clinical relevance of the knowledge acquired from experimental studies about the role of […]
• Psoriatic arthritis: important aspects for the dermatological practice
  CONCLUSION: In recent years it has become increasingly less complicated to effectively and safely treat all clinical facets of psoriasis and psoriatic arthritis within the framework of monotherapy. Dermatologists are important sentinels when it comes to early diagnosis, which in turn is decisive for the long-term prognosis. The presence and extent of psoriatic arthritis are […]
• Utilities of Botulinum Toxins in Dermatology and Cosmetology
  Botulinum toxin (BoNT) is a neurotoxin produced by the Clostridium botulinum bacterium with a well-known efficacy and safety profile in the focal idiopathic hyperhidrosis treatment. BoNT comprises seven different neurotoxins; however, only toxins A and B are clinically employed. BoNT is lately practiced in off-label therapies for a variety of skin diseases. Scar prevention, hyperhidrosis, […]